<DOC>
	<DOCNO>NCT01457573</DOCNO>
	<brief_summary>A single center , pilot trial combination therapy tamsulosin solifenacin 20 men symptomatic low urinary tract symptom ( LUTS ) . Subjects evaluate baseline , 1 , 2 , 3 month urinary NGF , urine creatinine , NGF/CR ratio patient report outcome .</brief_summary>
	<brief_title>Pilot Trial Of Urinary Nerve Growth Factor ( NGF ) As Biomarker Male Lower Urinary Tract Symptoms</brief_title>
	<detailed_description />
	<mesh_term>Lower Urinary Tract Symptoms</mesh_term>
	<mesh_term>Tamsulosin</mesh_term>
	<mesh_term>Solifenacin Succinate</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Men &gt; 50 year old symptomatic LUTS ( clinical BPH ) IPSS &gt; 8 PSA &lt; 10 ( negative biopsy within 6 month agespecific PSA elevation suspicious prostate carcinoma ) Post void residual urine &lt; 150 ml Urinary Flow rate &gt; 15 mL/sec Neurogenic bladder Urinary tract infection , Urinary stone ( ) , Urinary tract tumor Radiation therapy urologic malignancy prostate surgery ; radiation pelvic , colon , rectum , prostate , bladder , uterus ovary Alpha blocker therapy anticholinergic therapy within 3 month entry 5 alpha reductase therapy within 18 month . History cataract plan surgery</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>